- Home
- CHRS vs EMF Comparison
CHRS vs EMF Comparison
Compare CHRS & EMF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- EMF
- Stock Information
- Founded
- CHRS 2010
- EMF 1987
- Country
- CHRS United States
- EMF United States
- Employees
- CHRS N/A
- EMF N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- EMF Finance/Investors Services
- Sector
- CHRS Health Care
- EMF Finance
- Exchange
- CHRS Nasdaq
- EMF Nasdaq
- Market Cap
- CHRS 84.2M
- EMF 219.3M
- IPO Year
- CHRS 2014
- EMF N/A
- Fundamental
- Price
- CHRS $0.95
- EMF $14.88
- Analyst Decision
- CHRS Buy
- EMF
- Analyst Count
- CHRS 3
- EMF 0
- Target Price
- CHRS $4.68
- EMF N/A
- AVG Volume (30 Days)
- CHRS 1.3M
- EMF 29.3K
- Earning Date
- CHRS 08-07-2025
- EMF 01-01-0001
- Dividend Yield
- CHRS N/A
- EMF 6.16%
- EPS Growth
- CHRS N/A
- EMF N/A
- EPS
- CHRS N/A
- EMF N/A
- Revenue
- CHRS $272,251,000.00
- EMF N/A
- Revenue This Year
- CHRS N/A
- EMF N/A
- Revenue Next Year
- CHRS $99.43
- EMF N/A
- P/E Ratio
- CHRS $2.07
- EMF N/A
- Revenue Growth
- CHRS 19.87
- EMF N/A
- 52 Week Low
- CHRS $0.66
- EMF $10.58
- 52 Week High
- CHRS $2.43
- EMF $12.67
- Technical
- Relative Strength Index (RSI)
- CHRS 59.04
- EMF 73.41
- Support Level
- CHRS $0.73
- EMF $14.78
- Resistance Level
- CHRS $0.82
- EMF $14.99
- Average True Range (ATR)
- CHRS 0.04
- EMF 0.18
- MACD
- CHRS 0.02
- EMF 0.02
- Stochastic Oscillator
- CHRS 88.02
- EMF 92.04
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.